Brought to you by 
Novartis Venture Funds leads $7mm Series A1 financing for Neurovance; adds $6.3mm
03 Apr 2014
Executive Summary
Returning backer Novartis Venture Fund has led a $7mm Series A1 round for CNS-focused Neurovance Inc. The financing, which is split into three tranches that will be paid upon reaching certain milestones, also included other existing shareholders Venture Investors, H&Q Healthcare Investors, H&Q Life Sciences Investors, GBS Venture Partners, State of Wisconsin Investment Board, and Neurovance board member Timothy Barberich.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis Venture Funds leads $7mm Series A1 financing for Neurovance; adds $6.3mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice